FAQ
Reta-B1 frequently asked questions
What is Reta-B1?
Reta-B1™ is the technical identity of Rethiamine™, a proprietary Panacea Bio Chem research formulation containing a 5 mg retatrutide lower layer and a 20 mg thiamine upper layer, co-lyophilised as a dual-layer Peptourbillon™ inside Lyoprester SS™ and reconstituted with 0.5 mL P-EARLs™.
Is Reta-B1 the same formulation as Rethiamine and RetaBone?
Yes. Rethiamine™, Reta-B1™ and RetaBone™ are complementary identities for one proprietary Panacea Bio Chem research formulation. Rethiamine is the product name, Reta-B1 is the technical and evidence identity, and RetaBone is the metabolic and body-composition research identity. It is not three formulas.
Does retatrutide deplete vitamin B1?
It has not been established that retatrutide directly depletes thiamine. The more plausible concern is indirect: substantial appetite suppression, reduced food intake, rapid weight loss or prolonged gastrointestinal symptoms may increase the risk of inadequate micronutrient intake in susceptible individuals.
Why does the formulation propose 20 mg of thiamine?
The proposed 20 mg inclusion is a Panacea Bio Chem formulation-development strength. It is not presented as an established clinical requirement for individuals receiving retatrutide. Its suitability must be determined through dose justification, route-specific safety evaluation and measurements of thiamine status.
Why a weekly thiamine component?
Retatrutide supplies weekly pharmacological exposure. Reta-B1 investigates whether a thiamine replenishment component can be integrated into the same weekly administration event. It does not yet claim sustained seven-day thiamine release.
Why are retatrutide and thiamine lyophilised as two separate layers?
A peptide and a small-molecule vitamin have different pH, pI, ionic-strength and solubility requirements. The dual-layer Peptourbillon™ keeps them spatially separated during freezing, co-lyophilisation and storage, rather than storing them as one premixed liquid.
Is Reta-B1 an approved medicine?
No. Retatrutide is investigational, and the Reta-B1 formulation has not been approved as a medicinal product. It has not been established to prevent or treat thiamine deficiency, muscle loss, bone loss or any disease.
Where is the evidence behind these pages?
The research library lists every primary reference with what each study supports, what it does not show, its limitations and its conflicts, alongside the date of the last evidence search.
For the referenced detail behind every answer, open the research library or the depletion evidence review.